GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Joinn Laboratories (China) Co Ltd (HKSE:06127) » Definitions » Net Change in Cash

Joinn Laboratories (China) Co (HKSE:06127) Net Change in Cash : HK$-2,355 Mil (TTM As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Joinn Laboratories (China) Co Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Joinn Laboratories (China) Co's Net Change in Cash for the three months ended in Mar. 2025 was HK$-309 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2025 was HK$-2,355 Mil.

Joinn Laboratories (China) Co Net Change in Cash Historical Data

The historical data trend for Joinn Laboratories (China) Co's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Joinn Laboratories (China) Co Net Change in Cash Chart

Joinn Laboratories (China) Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only 151.84 4,708.51 -1,396.93 -50.12 -2,016.24

Joinn Laboratories (China) Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.68 -761.25 -350.21 -934.13 -309.47

Joinn Laboratories (China) Co Net Change in Cash Calculation

Joinn Laboratories (China) Co's Net Change in Cash for the fiscal year that ended in Dec. 2024 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=361.865+-2095.866+-283.603+1.366
=-2,016

Joinn Laboratories (China) Co's Net Change in Cash for the quarter that ended in Mar. 2025

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=69.854+-358.077+-20.013+-1.237
=-309

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$-2,355 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Joinn Laboratories (China) Co Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Joinn Laboratories (China) Co's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Joinn Laboratories (China) Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Joinn Laboratories (China) Co Ltd (HKSE:06127) » Definitions » Net Change in Cash
Comparable Companies
SHSE:603108 SHSE:603882 SZSE:300244 SZSE:300685 SZSE:300406 SZSE:300463 SZSE:000710 SZSE:300439 SZSE:301060 SZSE:300396 TMO DHR XSWX:LONN IDXX A IQV SHSE:603259 MTD NTRA WAT
Traded in Other Exchanges
603127:China
Address
A5 Rongjing East Street, Beijing Economic-Technological Development Area, Beijing, CHN, 100176
Website
https://www.joinnlabs.com
Joinn Laboratories (China) Co Ltd is a non-clinical contract research organization(CRO) focused on drug safety assessment. It operates in three segments: Non-clinical studies services include drug safety assessment, drug metabolism & pharmacokinetics (DMPK) studies, & pharmacology & efficacy studies; Clinical trial & related services segment provides early-stage services such as clinical CRO services, co-managed phase I clinical research units, & bioanalytical services, and: Sales of research models engages in the design, production, breeding, & sales of research models, currently including non-human primates and rodents. The majority is from the Non- Clinical studies services. Its geographical segments are China, the United States, and Other countries, of which the majority is from China.
Executives
Yi Fang Da Ji Jin Guan Li You Xian Gong Si 2102 Investment manager
Futu Trustee Limited 2301 Trustee
Ubs Group Ag 2201 Interest of corporation controlled by you
Aggregate Of Abrdn Plc Affiliated Investment Management Entities 2102 Investment manager
Fil Limited 2201 Interest of corporation controlled by you
Pandanus Associates Inc. 2201 Interest of corporation controlled by you
Pandanus Partners L.p. 2201 Interest of corporation controlled by you
Brown Brothers Harriman & Co. 2502 Approved lending agent
Fidelity Funds 2101 Beneficial owner
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Abrdn Asia Focus Plc 2101 Beneficial owner
Morgan Stanley 2201 Interest of corporation controlled by you
The Goldman Sachs Group, Inc. 2201 Interest of corporation controlled by you
Apg Asset Management N.v. 2101 Beneficial owner
Apg Groep N.v. 2101 Beneficial owner

Joinn Laboratories (China) Co Headlines

No Headlines